OA11644A - Method of dna vaccination. - Google Patents

Method of dna vaccination. Download PDF

Info

Publication number: OA11644A
Authority: OA; OAPI
Prior art keywords: formyl; hydroxyphenoxy; acid; administration; compound
Prior art date: 1998-08-26

Application number

OA1200100050A

Other languages

English (en)

Inventor

Jehad Charo

Rolf Kiessling

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-26

Filing date

1999-08-25

Publication date

2004-11-22

1999-08-25 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-11-22 Publication of OA11644A publication Critical patent/OA11644A/en

Links

238000000034 method Methods 0.000 title claims abstract description 50
238000011238 DNA vaccination Methods 0.000 title description 19
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 claims abstract description 75
150000001875 compounds Chemical class 0.000 claims abstract description 51
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 51
230000000890 antigenic effect Effects 0.000 claims abstract description 27
239000013598 vector Substances 0.000 claims abstract description 20
241000124008 Mammalia Species 0.000 claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
201000010099 disease Diseases 0.000 claims abstract description 12
230000024932 T cell mediated immunity Effects 0.000 claims abstract description 8
230000028996 humoral immune response Effects 0.000 claims abstract description 8
230000004044 response Effects 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 13
238000007920 subcutaneous administration Methods 0.000 claims description 12
229960005486 vaccine Drugs 0.000 claims description 12
238000007918 intramuscular administration Methods 0.000 claims description 9
IPRPPFIAVHPVJH-UHFFFAOYSA-N (4-hydroxyphenyl)acetaldehyde Chemical compound OC1=CC=C(CC=O)C=C1 IPRPPFIAVHPVJH-UHFFFAOYSA-N 0.000 claims description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
230000002685 pulmonary effect Effects 0.000 claims description 6
WWDIMPQSVRVLFI-UHFFFAOYSA-N 2-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1COC1=CC=CC(O)=C1C=O WWDIMPQSVRVLFI-UHFFFAOYSA-N 0.000 claims description 5
KPACGYPPYXMYIQ-UHFFFAOYSA-N 4-(2-formyl-3-hydroxyphenoxy)butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(O)=C1C=O KPACGYPPYXMYIQ-UHFFFAOYSA-N 0.000 claims description 5
VXEVAZSHSAXJNH-UHFFFAOYSA-N 5-(2-formyl-3-hydroxy-4-methoxyphenoxy)pentanoic acid Chemical compound COC1=CC=C(OCCCCC(O)=O)C(C=O)=C1O VXEVAZSHSAXJNH-UHFFFAOYSA-N 0.000 claims description 5
VFKFAELUHMKKKB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxy-4-propoxyphenoxy)pentanoic acid Chemical compound CCCOC1=CC=C(OCCCCC(O)=O)C(C=O)=C1O VFKFAELUHMKKKB-UHFFFAOYSA-N 0.000 claims description 5
XPKJLBBVFHFSEM-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCOC1=CC=CC(O)=C1C=O XPKJLBBVFHFSEM-UHFFFAOYSA-N 0.000 claims description 5
URGSRYJANOBLBB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-n-propan-2-ylpentanamide Chemical compound CC(C)NC(=O)CCCCOC1=CC=CC(O)=C1C=O URGSRYJANOBLBB-UHFFFAOYSA-N 0.000 claims description 5
AEYWTWGAFMYRFW-UHFFFAOYSA-N 5-(4-chloro-2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=C(Cl)C(O)=C1C=O AEYWTWGAFMYRFW-UHFFFAOYSA-N 0.000 claims description 5
QYQYFTULSFTJRU-UHFFFAOYSA-N 6-(2-formyl-3-hydroxyphenoxy)hexanoic acid Chemical compound OC(=O)CCCCCOC1=CC=CC(O)=C1C=O QYQYFTULSFTJRU-UHFFFAOYSA-N 0.000 claims description 5
DGVPMYXLJJNSOU-UHFFFAOYSA-N 7-(2-formyl-3-hydroxyphenoxy)heptanoic acid Chemical compound OC(=O)CCCCCCOC1=CC=CC(O)=C1C=O DGVPMYXLJJNSOU-UHFFFAOYSA-N 0.000 claims description 5
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 5
GVQLLDWWYDKCAL-UHFFFAOYSA-N benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate Chemical compound OC1=CC=CC(OCCCCC(=O)OCC=2C=CC=CC=2)=C1C=O GVQLLDWWYDKCAL-UHFFFAOYSA-N 0.000 claims description 5
PVPWPJFEUIVMSW-UHFFFAOYSA-N ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate Chemical compound CCOC(=O)CCCCOC1=CC=CC(O)=C1C=O PVPWPJFEUIVMSW-UHFFFAOYSA-N 0.000 claims description 5
GHVNNICPZOBPSX-UHFFFAOYSA-N 2-hydroxy-6-[[4-(2h-tetrazol-5-yl)phenyl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OCC=2C=CC(=CC=2)C=2NN=NN=2)=C1C=O GHVNNICPZOBPSX-UHFFFAOYSA-N 0.000 claims description 4
XGCPUNMNOGIEFL-UHFFFAOYSA-N 3-(2-formyl-3-hydroxyphenoxy)propanenitrile Chemical compound OC1=CC=CC(OCCC#N)=C1C=O XGCPUNMNOGIEFL-UHFFFAOYSA-N 0.000 claims description 4
SLOWFFLRNJZBAZ-UHFFFAOYSA-N 3-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C(=C(O)C=CC=2)C=O)=C1 SLOWFFLRNJZBAZ-UHFFFAOYSA-N 0.000 claims description 4
SSKKREZNXCEIJS-UHFFFAOYSA-N 4-[(3-acetamido-2-formylphenoxy)methyl]benzoic acid Chemical compound CC(=O)NC1=CC=CC(OCC=2C=CC(=CC=2)C(O)=O)=C1C=O SSKKREZNXCEIJS-UHFFFAOYSA-N 0.000 claims description 4
FRXRLTATMMDVNZ-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanamide Chemical compound NC(=O)CCCCOC1=CC=CC(O)=C1C=O FRXRLTATMMDVNZ-UHFFFAOYSA-N 0.000 claims description 4
FYUSDHGUBKZBON-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanenitrile Chemical compound OC1=CC=CC(OCCCCC#N)=C1C=O FYUSDHGUBKZBON-UHFFFAOYSA-N 0.000 claims description 4
JLGXUFPZHQHMKN-UHFFFAOYSA-N 5-(3-acetamido-2-formylphenoxy)pentanoic acid Chemical compound CC(=O)NC1=CC=CC(OCCCCC(O)=O)=C1C=O JLGXUFPZHQHMKN-UHFFFAOYSA-N 0.000 claims description 4
IUFNEZRKCZYFSG-UHFFFAOYSA-N 5-(4,6-dichloro-2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=C(Cl)C=C(Cl)C(O)=C1C=O IUFNEZRKCZYFSG-UHFFFAOYSA-N 0.000 claims description 4
AELJSHCCSWZMLX-UHFFFAOYSA-N ethyl 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1COC1=CC=CC(O)=C1C=O AELJSHCCSWZMLX-UHFFFAOYSA-N 0.000 claims description 4
JUXODYXAYBHXFN-UHFFFAOYSA-N methyl 3-[(2-formyl-3-hydroxyphenoxy)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(COC=2C(=C(O)C=CC=2)C=O)=C1 JUXODYXAYBHXFN-UHFFFAOYSA-N 0.000 claims description 4
150000003536 tetrazoles Chemical class 0.000 claims description 4
KBWBGANILAOXHI-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-n-methylsulfonylpentanamide Chemical compound CS(=O)(=O)NC(=O)CCCCOC1=CC=CC(O)=C1C=O KBWBGANILAOXHI-UHFFFAOYSA-N 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 2
229950009795 tucaresol Drugs 0.000 abstract description 64
150000003839 salts Chemical class 0.000 abstract description 3
150000002148 esters Chemical class 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 60
239000013612 plasmid Substances 0.000 description 54
108020004414 DNA Proteins 0.000 description 40
238000002649 immunization Methods 0.000 description 40
210000004027 cell Anatomy 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 27
108091028043 Nucleic acid sequence Proteins 0.000 description 26
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 26
239000002671 adjuvant Substances 0.000 description 25
230000000694 effects Effects 0.000 description 25
238000002255 vaccination Methods 0.000 description 22
230000028993 immune response Effects 0.000 description 20
102000011931 Nucleoproteins Human genes 0.000 description 19
108010061100 Nucleoproteins Proteins 0.000 description 19
239000000427 antigen Substances 0.000 description 19
108091007433 antigens Proteins 0.000 description 17
102000036639 antigens Human genes 0.000 description 17
238000009472 formulation Methods 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 15
230000005875 antibody response Effects 0.000 description 14
101150086609 groEL2 gene Proteins 0.000 description 14
108090000695 Cytokines Proteins 0.000 description 13
102000004127 Cytokines Human genes 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 12
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 10
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
230000005867 T cell response Effects 0.000 description 10
210000001744 T-lymphocyte Anatomy 0.000 description 10
241000700605 Viruses Species 0.000 description 10
210000004881 tumor cell Anatomy 0.000 description 10
108010041986 DNA Vaccines Proteins 0.000 description 9
229940021995 DNA vaccine Drugs 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
241000725303 Human immunodeficiency virus Species 0.000 description 8
239000002158 endotoxin Substances 0.000 description 8
229920006008 lipopolysaccharide Polymers 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
206010022000 influenza Diseases 0.000 description 7
241000712461 unidentified influenza virus Species 0.000 description 7
206010046865 Vaccinia virus infection Diseases 0.000 description 6
230000009089 cytolysis Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000002245 particle Substances 0.000 description 6
DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
238000011282 treatment Methods 0.000 description 6
208000007089 vaccinia Diseases 0.000 description 6
108010074032 HLA-A2 Antigen Proteins 0.000 description 5
102000025850 HLA-A2 Antigen Human genes 0.000 description 5
230000037453 T cell priming Effects 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000011830 transgenic mouse model Methods 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
230000002101 lytic effect Effects 0.000 description 4
-1 methyl 3-(2-formyl-3-hydroxyphenôxy)methylbenzoate Chemical compound 0.000 description 4
FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 4
241000894007 species Species 0.000 description 4
238000012360 testing method Methods 0.000 description 4
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 3
XHBZOAYMBBUURD-UHFFFAOYSA-N 1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(O)C=C1O XHBZOAYMBBUURD-UHFFFAOYSA-N 0.000 description 3
NRIVMXXOUOBRAG-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetaldehyde Chemical compound COC1=CC=C(CC=O)C=C1 NRIVMXXOUOBRAG-UHFFFAOYSA-N 0.000 description 3
KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 3
LTMWBQRMYYUNSH-UHFFFAOYSA-N 3-hydroxy-1-(4-methoxyphenyl)-3-methylbutan-2-one Chemical compound COC1=CC=C(CC(=O)C(C)(C)O)C=C1 LTMWBQRMYYUNSH-UHFFFAOYSA-N 0.000 description 3
AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 3
BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 3
GIDHSKDNBMVXFT-UHFFFAOYSA-N 5,6-dihydroxy-2-(4-hydroxyphenyl)chromene-3,4-dione Chemical compound C1=CC(O)=CC=C1C1C(=O)C(=O)C2=C(O)C(O)=CC=C2O1 GIDHSKDNBMVXFT-UHFFFAOYSA-N 0.000 description 3
POUITAHNNRJWMA-UHFFFAOYSA-N 5-hydroxybenzofuran-2-one Chemical compound OC1=CC=C2OC(=O)CC2=C1 POUITAHNNRJWMA-UHFFFAOYSA-N 0.000 description 3
BRCPWISABURVIH-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C1C=CC=C2OC BRCPWISABURVIH-UHFFFAOYSA-N 0.000 description 3
IRUHWRSITUYICV-UHFFFAOYSA-N 6-hydroxy-4-methylchromen-2-one Chemical compound C1=CC(O)=CC2=C1OC(=O)C=C2C IRUHWRSITUYICV-UHFFFAOYSA-N 0.000 description 3
CQWXLWDPFSPVHK-UHFFFAOYSA-N 6-hydroxynaphthalene-1,2-dione Chemical compound O=C1C(=O)C=CC2=CC(O)=CC=C21 CQWXLWDPFSPVHK-UHFFFAOYSA-N 0.000 description 3
MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 3
GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 3
NUJXPZCMZLDPOM-UHFFFAOYSA-N 8,10-dioxoundecanoic acid Chemical compound CC(=O)CC(=O)CCCCCCC(O)=O NUJXPZCMZLDPOM-UHFFFAOYSA-N 0.000 description 3
BTYBORAHYUCUMH-UHFFFAOYSA-N 8-methoxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=C1C=CC=C2OC BTYBORAHYUCUMH-UHFFFAOYSA-N 0.000 description 3
241000193830 Bacillus <bacterium> Species 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 3
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
239000002262 Schiff base Substances 0.000 description 3
150000004753 Schiff bases Chemical class 0.000 description 3
101710090322 Truncated surface protein Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 3
230000007815 allergy Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000010276 construction Methods 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000002615 epidermis Anatomy 0.000 description 3
TZMFJUDUGYTVRY-UHFFFAOYSA-N ethyl methyl diketone Natural products CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 3
239000008187 granular material Substances 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000036039 immunity Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229960003130 interferon gamma Drugs 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 3
229940117954 naringenin Drugs 0.000 description 3
WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 3
235000007625 naringenin Nutrition 0.000 description 3
SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 3
229940100595 phenylacetaldehyde Drugs 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
SICBLYCPRWNHHP-UHFFFAOYSA-N 1,2-bis(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(OC)C=C1 SICBLYCPRWNHHP-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
RNDNSYIPLPAXAZ-UHFFFAOYSA-N 2-Phenyl-1-propanol Chemical compound OCC(C)C1=CC=CC=C1 RNDNSYIPLPAXAZ-UHFFFAOYSA-N 0.000 description 2
239000001431 2-methylbenzaldehyde Substances 0.000 description 2
WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 2
XEAPZXNZOJGVCZ-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(OC)=CC=C21 XEAPZXNZOJGVCZ-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
241000283707 Capra Species 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
229910052693 Europium Inorganic materials 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
241000186779 Listeria monocytogenes Species 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
208000030852 Parasitic disease Diseases 0.000 description 2
101900083372 Rabies virus Glycoprotein Proteins 0.000 description 2
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
239000011324 bead Substances 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000012636 effector Substances 0.000 description 2
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000002434 immunopotentiative effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
229940115931 listeria monocytogenes Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
238000003305 oral gavage Methods 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
229910052722 tritium Inorganic materials 0.000 description 2
239000012646 vaccine adjuvant Substances 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical group C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
208000035049 Blood-Borne Infections Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
101710163595 Chaperone protein DnaK Proteins 0.000 description 1
108010059013 Chaperonin 10 Proteins 0.000 description 1
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
241001185363 Chlamydiae Species 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108010081396 EBNA4 antigen Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
101710147543 Epstein-Barr nuclear antigen leader protein Proteins 0.000 description 1
206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
201000006353 Filariasis Diseases 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
101710113864 Heat shock protein 90 Proteins 0.000 description 1
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000985215 Homo sapiens 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
101000854936 Homo sapiens Visual system homeobox 1 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
101150027427 ICP4 gene Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
241000186366 Mycobacterium bovis Species 0.000 description 1
101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 description 1
108010048712 Mycobacterium tuberculosis Ag38 antigen Proteins 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
101150118742 NP gene Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000220010 Rhode Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
241000713311 Simian immunodeficiency virus Species 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
101800000385 Transmembrane protein Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001355 anti-mycobacterial effect Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003926 antimycobacterial agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
101150028082 fbpA gene Proteins 0.000 description 1
101150020570 fbpC gene Proteins 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000017307 interleukin-4 production Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
238000013507 mapping Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229940032362 superoxide dismutase Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000001890 transfection Methods 0.000 description 1
201000002311 trypanosomiasis Diseases 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200100050A 1998-08-26 1999-08-25 Method of dna vaccination. OA11644A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9818627.3A GB9818627D0 (en)	1998-08-26	1998-08-26	Improvements in dva vaccination

Publications (1)

Publication Number	Publication Date
OA11644A true OA11644A (en)	2004-11-22

Family

ID=10837881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100050A OA11644A (en)	1998-08-26	1999-08-25	Method of dna vaccination.

Country Status (22)

Country	Link
US (1)	US7074770B1 (de)
EP (1)	EP1107785B1 (de)
JP (1)	JP2002523469A (de)
KR (1)	KR20010072983A (de)
CN (1)	CN1326358A (de)
AT (1)	ATE411043T1 (de)
AU (1)	AU747643B2 (de)
BR (1)	BR9913323A (de)
CA (1)	CA2341544A1 (de)
CZ (1)	CZ2001717A3 (de)
DE (1)	DE69939747D1 (de)
ES (1)	ES2313791T3 (de)
GB (1)	GB9818627D0 (de)
HU (1)	HUP0103214A3 (de)
IL (1)	IL141623A0 (de)
NO (1)	NO20010922L (de)
NZ (1)	NZ510206A (de)
OA (1)	OA11644A (de)
PL (1)	PL346299A1 (de)
TR (1)	TR200101256T2 (de)
WO (1)	WO2000012121A1 (de)
ZA (1)	ZA200101539B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7223739B1 (en)	1995-06-07	2007-05-29	Powderject Vaccines, Inc.	Adjuvanted genetic vaccines
WO2000047227A2 (en)	1999-02-09	2000-08-17	Powderject Vaccines, Inc.	Mycobacterium tuberculosis, immunization
GB9923309D0 (en) *	1999-10-01	1999-12-08	Glaxo Group Ltd	Assay
PT1913957E (pt) *	1999-11-03	2010-05-05	Powderject Vaccines Inc	Vacinas genéticas adjuvantes
DK1913957T3 (da) *	1999-11-03	2010-05-10	Powderject Vaccines Inc	Genetiske adjuvant-vacciner
WO2001076626A2 (en) *	2000-04-11	2001-10-18	Galenica Pharmaceuticals, Inc.	Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
GB0023008D0 (en) *	2000-09-20	2000-11-01	Glaxo Group Ltd	Improvements in vaccination
CA2530374C (en) *	2003-06-27	2012-05-15	Kyowa Hakko Kogyo Co., Ltd.	Hsp90 family protein inhibitors
CN100415876C (zh) *	2003-09-05	2008-09-03	杭州浙大康泰生物技术有限公司	艾滋病重组腺病毒疫苗
CN102770156B (zh)	2009-12-16	2016-01-20	克洛恩泰克制药股份公司	密码子优化的乙型肝炎病毒核心抗原(hbcag)
AU2012270015A1 (en)	2011-06-15	2014-01-16	Chrontech Pharma Ab	Injection needle and device
ES2790358T3 (es)	2011-12-28	2020-10-27	Global Blood Therapeutics Inc	Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
CA3142817A1 (en) *	2011-12-28	2013-07-04	Global Blood Therapeutics, Inc.	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014064534A2 (en)	2012-10-05	2014-05-01	Chrontech Pharma Ab	Injection needle, device, immunogenic compositions and method of use
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
CN112500338A (zh)	2013-03-15	2021-03-16	全球血液疗法股份有限公司	化合物及其用于调节血红蛋白的用途
US10100043B2 (en)	2013-03-15	2018-10-16	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EP3919056B1 (de)	2013-03-15	2024-08-28	Global Blood Therapeutics, Inc.	Verbindungen und verwendungen davon zur modulation von hämoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (de)	2013-03-15	2021-01-20	Global Blood Therapeutics, Inc.	Verbindungen und verwendungen davon zur modulation von hämoglobin
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
SG10201911662YA (en)	2014-02-07	2020-02-27	Global Blood Therapeutics Inc	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MX382936B (es) *	2014-02-26	2025-03-11	Univ Texas	Liberación de protones de nitrobenzaldehído para la manipulación de la acidosis celular.
HK1249052A1 (zh)	2015-03-06	2018-10-26	BeyondSpring Pharmaceuticals Inc.	治疗与ras突变相关的癌症的方法
US11267807B2 (en) *	2015-10-28	2022-03-08	The Brigham And Women's Hospital, Inc.	Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy
HUE072191T2 (hu)	2015-12-04	2025-10-28	Global Blood Therapeutics Inc	A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje
SG11201806583XA (en)	2016-02-08	2018-09-27	Beyondspring Pharmaceuticals Inc	Compositions containing tucaresol or its analogs
TWI825524B (zh)	2016-05-12	2023-12-11	美商全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
BR112018074990A2 (pt)	2016-06-06	2019-03-12	Beyondspring Pharmaceuticals, Inc.	composição, usos e método para reduzir neutropenia
TWI778983B (zh)	2016-10-12	2022-10-01	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11633393B2 (en)	2017-01-06	2023-04-25	Beyondspring Pharmaceuticals, Inc.	Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (de)	2017-02-01	2020-11-25	Beyondspring Pharmaceuticals, Inc.	Verfahren zur reduzierung von neutropenie
KR20200112881A (ko)	2018-01-24	2020-10-05	비욘드스프링 파마수티컬스, 인코포레이티드.	플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109232238B (zh) *	2018-08-29	2022-05-17	北京勤邦生物技术有限公司	吉非罗齐半抗原、人工抗原和抗体及其制备方法和用途
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin
CN112778155B (zh) *	2019-11-11	2023-08-11	大连万春布林医药有限公司	妥卡雷琐衍生物及其用途
AU2020464868A1 (en) *	2020-08-26	2023-04-13	Gertrude Biomedical Pty Ltd	Antiviral SOX inhibitors
EP4319751A4 (de)	2021-04-09	2025-02-26	Beyondspring Pharmaceuticals, Inc.	Therapeutische zusammensetzungen und verfahren zur behandlung von tumoren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5620896A (en) *	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
ES2096215T3 (es) *	1992-10-01	1997-03-01	Wellcome Found	Tucaresol como agente inmunopotenciador.
TW404844B (en) *	1993-04-08	2000-09-11	Oxford Biosciences Ltd	Needleless syringe
EP1170368B1 (de)	1994-01-27	2010-07-28	University Of Massachusetts Medical Center	Immunisierung durch Impfung von DNS Transkriptionseinheit

1998
- 1998-08-26 GB GBGB9818627.3A patent/GB9818627D0/en not_active Ceased
1999
- 1999-08-25 IL IL14162399A patent/IL141623A0/xx unknown
- 1999-08-25 NZ NZ510206A patent/NZ510206A/en unknown
- 1999-08-25 OA OA1200100050A patent/OA11644A/en unknown
- 1999-08-25 AT AT99944505T patent/ATE411043T1/de not_active IP Right Cessation
- 1999-08-25 BR BR9913323-7A patent/BR9913323A/pt not_active IP Right Cessation
- 1999-08-25 AU AU57402/99A patent/AU747643B2/en not_active Ceased
- 1999-08-25 WO PCT/EP1999/006217 patent/WO2000012121A1/en not_active Ceased
- 1999-08-25 DE DE69939747T patent/DE69939747D1/de not_active Expired - Lifetime
- 1999-08-25 ES ES99944505T patent/ES2313791T3/es not_active Expired - Lifetime
- 1999-08-25 JP JP2000567235A patent/JP2002523469A/ja active Pending
- 1999-08-25 CA CA002341544A patent/CA2341544A1/en not_active Abandoned
- 1999-08-25 EP EP99944505A patent/EP1107785B1/de not_active Expired - Lifetime
- 1999-08-25 TR TR2001/01256T patent/TR200101256T2/xx unknown
- 1999-08-25 KR KR1020017002431A patent/KR20010072983A/ko not_active Withdrawn
- 1999-08-25 CN CN99812463A patent/CN1326358A/zh active Pending
- 1999-08-25 US US09/763,462 patent/US7074770B1/en not_active Expired - Fee Related
- 1999-08-25 CZ CZ2001717A patent/CZ2001717A3/cs unknown
- 1999-08-25 PL PL99346299A patent/PL346299A1/xx not_active Application Discontinuation
- 1999-08-25 HU HU0103214A patent/HUP0103214A3/hu unknown
2001
- 2001-02-23 ZA ZA200101539A patent/ZA200101539B/en unknown
- 2001-02-23 NO NO20010922A patent/NO20010922L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL346299A1 (en)	2002-01-28
EP1107785B1 (de)	2008-10-15
AU747643B2 (en)	2002-05-16
JP2002523469A (ja)	2002-07-30
CN1326358A (zh)	2001-12-12
HUP0103214A2 (hu)	2001-12-28
CA2341544A1 (en)	2000-03-09
AU5740299A (en)	2000-03-21
ZA200101539B (en)	2002-02-25
BR9913323A (pt)	2001-12-04
TR200101256T2 (tr)	2001-10-22
ATE411043T1 (de)	2008-10-15
ES2313791T3 (es)	2009-03-01
GB9818627D0 (en)	1998-10-21
CZ2001717A3 (cs)	2001-10-17
NO20010922D0 (no)	2001-02-23
WO2000012121A1 (en)	2000-03-09
HUP0103214A3 (en)	2003-10-28
EP1107785A1 (de)	2001-06-20
DE69939747D1 (de)	2008-11-27
IL141623A0 (en)	2002-03-10
US7074770B1 (en)	2006-07-11
KR20010072983A (ko)	2001-07-31
NZ510206A (en)	2003-08-29
NO20010922L (no)	2001-04-23

Publication	Publication Date	Title
US7074770B1 (en)	2006-07-11	Method of DNA vaccination
Ghaffarifar	2018	Plasmid DNA vaccines: where are we now
JP5759980B2 (ja)	2015-08-05	癌および感染症に対する免疫療法組成物の組み合わせ
Iwasaki et al.	1997	The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
Giese	1998	DNA-antiviral vaccines: new developments and approaches—a review
JP2005526750A (ja)	2005-09-08	Ｃｅａ及びｃｄ４０リガンドをコードするｄｎａワクチン及びその使用方法
Kim et al.	1997	Development of a multicomponent candidate vaccine for HIV-1
US8053421B2 (en)	2011-11-08	DNA vaccines against tumor growth and methods of use thereof
Boyle et al.	2000	Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations
RU2495677C2 (ru)	2013-10-20	Сочетание рекомбинантной микробактерии и биологически активного средства в качестве вакцины
De Marco et al.	2003	DNA vaccines against HPV-16 E7-expressing tumour cells
Lisziewicz et al.	2007	The potential of topical DNA vaccines adjuvanted by cytokines
EP1401491A1 (de)	2004-03-31	Verfahren zur einleitung einer immunantwort mit einem hohen th1/th2 verhältnis, durch intrazelluläre stimulierung von nfkappab
US6358933B1 (en)	2002-03-19	Formulation of nucleic acid and acemannan
MXPA01002043A (en)	2002-03-05	Method of dna vaccination
Iwasaki et al.	1997	Both gene gun and intramuscular injection of plasmid DNA induce cytotoxic T-lymphocytes via bone marrow derived antigen presenting cells
AU2002314374A1 (en)	2003-01-21	Methods for inducing an immune response with an elevated TH1/TH2 ratio by intracellular induction of NFKAPPAB
Xing	2004	BCG and new tuberculosis vaccines
Webber	2001	Protection against leishmaniasis by DNA injection of a plasmid encoding the Leishmania major Cpn60 gene
HK1106929B (zh)	2013-02-01	作为疫苗的重组分枝杆菌和生物活性剂的组合